



**20th October 2008**

**NORGINE APPOINTS DR STUART DOLLOW AS CHIEF DEVELOPMENT OFFICER**

Dr Stuart Dollow will be joining Norgine as Chief Development Officer, with effect from 1st January 2009. Within this role, Stuart will have overall leadership responsibility for Medical, Clinical Development, Regulatory Affairs, and Product Development functions.

Stuart brings a wealth of experience, including time as a Clinical Research Physician with Roche followed by a variety of roles with GlaxoWellcome including Head of Medical Advisory Group, Primary Care Medical Head and Chair of the CNS European Business Team. Over the last five years Stuart has been working as Medical Director at GlaxoSmithKline.

Stuart is trained in both General Medicine and General Practice, and has a broad background in international clinical development management, and leadership in a commercial environment in both the US and Europe.

“I am confident that Stuart will make a huge contribution to our continued development as an organisation.” says Peter Martin, Chief Operating Officer at Norgine.

**ENDS**

**If you would like any further information, or to set up an interview please contact:**

Medicom Group: Olivia Spiro on 020 8481 8129 ([olivias@medicomgroup.com](mailto:olivias@medicomgroup.com))

**Notes to editor**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2007 Norgine's sales were €220 million, the 21st consecutive year of double-digit growth. The company employs over 1,000 people of whom around 400 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL<sup>®</sup> for the treatment of chronic constipation and faecal impaction,

MOVIPREP® a new generation bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. In addition to its site at Hengoes, Norgine also has a manufacturing site at Dreux in France.

Norgine's website is [www.norgine.com](http://www.norgine.com)